Immediate Impact
1 from Science/Nature 53 standout
Citing Papers
Extracellular vesicles in cancer´s communication: messages we can read and how to answer
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Evgeny Gotovkin being referenced
Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Evgeny Gotovkin | 149 | 74 | 113 | 4 | 199 | |
| Shu-Kui Qin | 122 | 43 | 175 | 8 | 259 | |
| Yuriy Ostapenko | 128 | 63 | 113 | 6 | 188 | |
| Martine Blazquez | 99 | 117 | 87 | 7 | 215 | |
| Kanwal Pratap Singh Raghav | 115 | 60 | 157 | 8 | 233 | |
| Leonie K. de Klerk | 83 | 55 | 114 | 4 | 214 | |
| L. A. A. Brosens | 92 | 133 | 165 | 5 | 299 | |
| C. Bessaguet | 123 | 104 | 80 | 7 | 180 | |
| E Volpin | 35 | 65 | 99 | 5 | 151 | |
| Najib Lamfichekh | 54 | 109 | 119 | 7 | 167 | |
| Michelle Marcovitz | 72 | 64 | 81 | 6 | 152 |
All Works
Loading papers...